BioArctic AB (STO:BIOAB), a research based biopharmaceutical company, on Tuesday reported profit of SEK15.2m, or EPS of SEK0.22, from January 2017 to December 2017.
This was a decline over profit of SEK57.6m, or EPS of SEK0.91, in 2016.
Net sales for the year amounted to SEK140.7m, as compared with SEK105.6m in 2016.
Also, the company's board of directors has proposed that that no dividend is paid for the financial year 2017.
BioArctic is focussed on disease modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company is also developing a treatment for complete spinal cord injury.
(EUR1.00=SEK9.99)
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement